An observational study in Schizophrenia, Major Depressive Disorder and Bipolar Disorder, sponsored by AstraZeneca. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2014-02-07.
Sponsored by AstraZeneca · Observational
The main objective of this observational study is to characterize new users of quetiapine XR as well as new users of other study drugs (i.e. the comparison group) and to quantify the risk of developing newly diagnosed outcomes of interest in new users of quetiapine XR as well as in other study drugs.
Epidemiology study to assess the safety of a new slow-release form of Seroquel (quetiapine) in the post-marketing phase in the UK.
3,471 studies on the registry are indexed under Schizophrenia; 472 are open to participants now.
This study's enrollment of 37,372 is above the median of 178 across 491 observational studies indexed under Schizophrenia.
Browse Schizophrenia studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
A sample of the general population in the UK consisting of 3 millions inhabitants.
Exclusion Criteria:
The outcome of interest will be evaluated by means of relative risk based on incidence rates estimates in users of quetiapine XR vs corresponding incidence rates in users of comparison drugs
Time frame: During follow-up of a treatment episode estimated to be on average of 1.5 years
Duration of treatment
Time frame: During follow-up estimated to be on average of 1.5 years.
Duration of treatment episode
Episode, defined as the treatment time from first to last prescription of quetiapine XR or other study drugs.
Time frame: During follow-up estimated to be on average of 1.5 years
Comorbidities defined by clinical diagnosis or prescription
Time frame: Baseline and during follow up of treatment estimated to be on average 1.5 years
Age
Time frame: Baseline
Gender
Time frame: Baseline
Dose
Time frame: During follow-up of treatment estimated to be on average 1.5 years
Adherence
Time frame: During follow-up of treatment estimated to be on average 1.5 years
The number of subjects to whom the drug was prescribed by the general practitioners.
The number of patients, whom the drug was prescribed by the specified type of prescriber (specialist, general practitioner or another type of physician).
Time frame: During follow-up of treatment estimated to be on average 1.5 years
Indication for treatment
Time frame: During follow-up of treatment estimated to be on averaged 1.5 years
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca